Hypoalbuminemia and hypercalcemia are independently associated with poor treatment outcomes of anti-PD-1 immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma-Reference-Cited by-同舟云学术

Hypoalbuminemia and hypercalcemia are independently associated with poor treatment outcomes of anti-PD-1 immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma

Published:2024-09-11 Issue:1 Volume:22 Page:
ISSN:1477-7819
Container-title:World Journal of Surgical Oncology
language:en
Short-container-title:World J Surg Onc

Author:

Chiu Tai-Jan,Huang Tai-Lin,Chien Chih-Yen,Huang Wan-Ting,Li Shau-Hsuan

Funder

Chang Gung Memorial Hospital

National Science Council, Taiwan

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12957-024-03522-2.pdf

Reference34 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.

2. National Department of Health. Taiwan, Republic of China Cancer Registry Annual Report 1972–2020.

3. Chen YH, Chien CY, Wang YM, Li SH. Serum levels of stromal cell-derived Factor-1alpha and vascular endothelial growth factor predict clinical outcomes in Head and Neck squamous cell carcinoma patients receiving TPF induction chemotherapy. Biomedicines 2022, 10(4).

4. Rajendra A, Noronha V, Joshi A, Patil VM, Menon N, Prabhash K. Palliative chemotherapy in head and neck cancer: balancing between beneficial and adverse effects. Expert Rev Anticancer Ther. 2020;20(1):17–29.

5. Cohen EEW, Soulieres D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–67.